Related Experiment Video
Updated: Mar 10, 2026
06:53
A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
Published on: December 26, 2015
13.2K
miRNA Targeting Drugs: The Next Blockbusters?
1BEROCEUTICA GmbH, c/o Universität Potsdam, August-Bebel-Strasse 89, 14482, Potsdam, Germany. marco.schmidt@beroceutica.com.
Methods in Molecular Biology (Clifton, N.J.)
|December 8, 2016
Summary
MicroRNAs (miRNAs), crucial gene regulators, show promise as drug targets. Developing miRNA-based drugs faces challenges but offers potential treatments for currently incurable diseases.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- MicroRNAs (miRNAs) are small, non-coding RNA molecules regulating gene expression post-transcriptionally.
- The discovery of miRNAs has opened new avenues for therapeutic interventions.
- Miravirsen, an miRNA-targeting drug, has shown success in Phase II trials for Hepatitis C.
Purpose of the Study:
- To highlight the therapeutic potential of miRNAs as drug targets.
- To discuss the inherent challenges in developing miRNA-based drugs.
- To provide a comprehensive overview of current miRNA drug discovery strategies.
Main Methods:
- Review of existing literature on miRNA biology and drug development.
- Analysis of clinical trial data for miRNA-targeting drugs.
- Exploration of novel chemical and pharmaceutical approaches for miRNA drug design.
Main Results:
- miRNAs represent a promising class of targets for treating various diseases.
- Significant challenges exist in achieving desired pharmacokinetic properties for miRNA drugs.
- Diverse strategies are emerging to overcome these drug development hurdles.
Conclusions:
- miRNA-targeting drugs offer potential cures for diseases currently deemed untreatable.
- Rethinking the drug discovery process is essential for successful miRNA-based therapeutics.
- Continued research into miRNA drug discovery is critical for future medical advancements.
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
01:26Targets for Drug Action: Overview
10.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.9K
01:22MicroRNAs
4.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
01:22MicroRNAs
24.5K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.5K
02:30siRNA - Small Interfering RNAs
18.9K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.9K
01:23RNA Interference
28.4K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.4K